{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-032851","form_type":"8-K","ticker":"ZVSA","cik":"0001859007","company_name":"ZyVersa Therapeutics, Inc.","filed_at":"2026-07-10T20:30:31+00:00","discovered_at":"2026-07-10T20:31:00.285247+00:00","generated_at":"2026-07-10T20:31:13.244303+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ZyVersa Therapeutics explores cost cuts, potential going dark, and asset sales; director Park resigns","bullets":["Director Min Chul Park resigned effective July 8, 2026, for personal reasons, no disagreement with company.","CEO Stephen Glover and CFO Peter Wolfe voluntarily accepted reduced compensation to preserve cash.","Company considering divesting VAR 200 or IC 100 product candidates and reducing headcount.","Company may go dark by suspending SEC reporting obligations under Rule 12h-3.","Also evaluating sale of company or assets, restructuring, or reorganization to maximize shareholder value."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-032851","json":"https://secwatch.observer/filing/0001493152-26-032851.json","markdown":"https://secwatch.observer/filing/0001493152-26-032851.md","text":"https://secwatch.observer/filing/0001493152-26-032851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/0001493152-26-032851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1859007/000149315226032851/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-10T20:31:13.244303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}